Pharmaceutical combinations for treating tumor comprising Anti-CD19 antibody and natural killer cell

UA131269C2Undetermined Publication Date: 2026-10-07GC CELL CORP +1

View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office: UA · UA
Patent Type: Patents
Current Assignee / Owner
Priority Date: 2019-09-05
Filing Date: 2019-09-05
Publication Date: 2026-10-07

Application Information

Patent Timeline

05 Sep 2019

Priority

05 Sep 2019

Application

07 Oct 2026

Publication

UA131269C2

CPC: A61P35/00; A61K39/3955; A61K2039/505; A61K2039/54; A61K2039/545; C07K16/2803; C07K16/2887; C07K2317/732

Inventors: Her Jung Hyun; Jung Mi Young

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

Provided is a pharmaceutical combination comprising an antibody specific for CD19 and a natural killer cell, and a treatment method using the same. Such a pharmaceutical combination is capable of exhibiting synergistic therapeutic effects on a malignant tumor of B-cell origin such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and / or acute lymphoblastic leukemia.

Need to check novelty before this filing date? Find Prior Art